September 1, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS SOMERSET, NJ — Solco Healthcare is proud to announce the FDA approval on April 7, 2022 and September 2022 availability of Nebivolol tablets, 2.5mg, 5mg, 10mg and 20mg an AB-rated equivalent to Bystolic® by Allergan, Inc. Nebivolol is a beta-adrenergic blocking agent indicated
Read more
August 11, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS SOMERSET, NJ — Solco Healthcare announces its FDA approval and availability of Tadalafil tablets, 2.5mg, 5mg, 10mg and 20mg, which are AB-rated generics equivalent to Cialis® and Adcirca® by Eli Lily. Tadalafil 2.5mg, 5mg, 10mg and 20mg tablets are indicated for the treatment
Read more
July 7, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR ENALAPRIL MALEATE TABLETS SOMERSET, NJ — Solco Healthcare announces its FDA approval for Enalapril Maleate tablets, 2.5mg, 5mg, 10mg and 20mg which are AB-rated equivalent to Vasotec® by Bausch Health. “This product was developed by our subsidiary – Prinbury Biopharm for Solco. This approval represents
Read more
THE FDA HAS OFFICIALLY REMOVED ZHEJIANG HUAHAI PHARMACEUTICAL FROM IMPORT ALERT Somerset, NJ, November 15, 2021 – Solco is pleased to announce that the FDA has lifted the ImportAlert (IA) 66-40, “Detention Without Physical Examination of Drugs From Firms Which Have Not MetDrug GMPs”, Published Date: 11/12/2021, from Zhejiang Huahai Pharmaceutical Co. Ltd., at CoastalIndustrial
Read more
SOMERSET, NJ — Solco Healthcare announces its FDA approval for Amphetamine Sulfate tablets, 5mg and 10mg, which is an AA-rated equivalent to Evekeo® by Arbor Pharmaceuticals. “This approval represents Solco’s first CII product within the ADHD therapeutic treatment. Amphetamine sulfate tablets will be manufactured in our Prinston Laboratories facility located in Charlotte, NC. We are
Read more
SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL CRANBURY, NJ — Solco Healthcare announces its FDA approval for Glycopyrrolate Injection, 0.2mg/mL, which is an AP-rated equivalent to Robinul® by Hikma. “We are very pleased to have received FDA approval for Glycopyrrolate injection. This approval represents a new chapter for Solco, as we enter
Read more
Read PDF here. http://www.solcohealthcare.com/uploads/news/Press-Release-Irbesartan-Recall.pdf
Read more
FOR IMMEDIATE RELEASE – CRANBURY, NEW JERSEY – December 14, 2018 On July 12, 2018, Prinston Pharmaceutical Inc. announced that one of its affiliated companies, Solco Healthcare, LLC, based in Cranbury, New Jersey, voluntarily recalled all lots of Valsartan Tablets, 40mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5g, 160mg/25mg, 320mg/12.5mg and 320mg/25mg, to the consumer
Read more
FOR IMMEDIATE RELEASE – CRANBURY, NEW JERSEY, August 21, 2018. Huahai US Inc., a subsidiary of Zhejiang Huahai Pharmaceutical Co. Ltd is issuing a statement. Recent articles in several print and on-line media have misrepresented information about the discovery of a trace amount of a genotoxic impurity in Valsartan, an active pharmaceutical ingredient (API) made
Read more
Read detail here: http://www.solcohealthcare.com/uploads/news/PressReleaseValsartanRecallFinal.pdf
Read more